Literature DB >> 22245499

Response of limbic neurotensin systems to methamphetamine self-administration.

G R Hanson1, A J Hoonakker, M E Alburges, L M McFadden, C M Robson, P S Frankel.   

Abstract

Methamphetamine (METH) abuse is personally and socially devastating. Although effects of METH on dopamine (DA) systems likely contribute to its highly addictive nature, no medications are approved to treat METH dependence. Thus, we and others have studied the METH-induced responses of neurotensin (NT) systems. NT is associated with inhibitory feedback action on DA projections, and NT levels are elevated in both the nucleus accumbens and dorsal striatum after noncontingent treatment with high doses of METH. In the present study, we used a METH self-administration (SA) model (linked to lever pressing) to demonstrate that substitution of an NT agonist for METH, while not significantly affecting motor activity, dramatically reduced lever pressing but was not self-administered per se. We also found that nucleus accumbens NT levels were elevated via a D1 mechanism after five sessions in rats self-administering METH (SAM), with a lesser effect in corresponding yoked rats. Extended (15 daily sessions) exposure to METH SA manifested similar NT responses; however, more detailed analyses revealed (i) 15 days of METH SA significantly elevated NT levels in the nucleus accumbens shell and dorsal striatum, but not the nucleus accumbens core, with a lesser effect in the corresponding yoked METH rats; (ii) the elevation of NT in both the nucleus accumbens shell and dorsal striatum significantly correlated with the total amount of METH received in the self-administering, but not the corresponding yoked METH rats; and (iii) an NT agonist blocked, but an NT antagonist did not alter, lever-pressing behavior on day 15 in SAM rats. After 5 days in SAM animals, NT levels were also elevated in the ventral tegmental area, but not frontal cortex of rats self-administering METH.
Copyright © 2011 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22245499      PMCID: PMC3275099          DOI: 10.1016/j.neuroscience.2011.12.037

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  35 in total

1.  Role of N-methyl-D-aspartate receptors in dopamine D1-, but not D2-, mediated changes in striatal and accumbens neurotensin systems.

Authors:  N A Singh; L G Bush; J W Gibb; G R Hanson
Journal:  Brain Res       Date:  1992-02-07       Impact factor: 3.252

Review 2.  Responses of limbic and extrapyramidal neurotensin systems to stimulants of abuse. Involvement of dopaminergic mechanisms.

Authors:  G R Hanson; N Singh; K Merchant; M Johnson; L Bush; J W Gibb
Journal:  Ann N Y Acad Sci       Date:  1992       Impact factor: 5.691

3.  Role of dopamine D-1 and D-2 receptors in the regulation of neurotensin systems of the neostriatum and the nucleus accumbens.

Authors:  K M Merchant; J W Gibb; G R Hanson
Journal:  Eur J Pharmacol       Date:  1989-02-07       Impact factor: 4.432

4.  Changes in the limbic neurotensin systems induced by dopaminergic drugs.

Authors:  K M Merchant; A A Letter; J W Gibb; G R Hanson
Journal:  Eur J Pharmacol       Date:  1988-08-09       Impact factor: 4.432

5.  Differential effects of cocaine and methamphetamine on neurotensin/neuromedin N and preprotachykinin messenger RNA expression in unique regions of the striatum.

Authors:  D H Adams; G R Hanson; K A Keefe
Journal:  Neuroscience       Date:  2001       Impact factor: 3.590

6.  Methylphenidate alters basal ganglia neurotensin systems through dopaminergic mechanisms: a comparison with cocaine treatment.

Authors:  Mario E Alburges; Amanda J Hoonakker; Kristen A Horner; Annette E Fleckenstein; Glen R Hanson
Journal:  J Neurochem       Date:  2011-03-15       Impact factor: 5.372

7.  Induction of neurotensin and c-fos mRNA in distinct subregions of rat neostriatum after acute methamphetamine: comparison with acute haloperidol effects.

Authors:  K M Merchant; G R Hanson; D M Dorsa
Journal:  J Pharmacol Exp Ther       Date:  1994-05       Impact factor: 4.030

8.  The neurotensin agonist PD149163 increases Fos expression in the prefrontal cortex of the rat.

Authors:  Kimberly A Petrie; Michael Bubser; Cheryl D Casey; M Duff Davis; Bryan L Roth; Ariel Y Deutch
Journal:  Neuropsychopharmacology       Date:  2004-10       Impact factor: 7.853

9.  Up-regulation of neurotensin mRNA in the rat striatum after acute methamphetamine treatment.

Authors:  M N Castel; P Morino; A Dagerlind; T Hökfelt
Journal:  Eur J Neurosci       Date:  1994-04-01       Impact factor: 3.386

10.  Neurotensin injected into the nucleus accumbens blocks the psychostimulant effects of cocaine but does not attenuate cocaine self-administration in the rat.

Authors:  P Robledo; R Maldonado; G F Koob
Journal:  Brain Res       Date:  1993-09-17       Impact factor: 3.252

View more
  15 in total

Review 1.  Dopamine D2 autoreceptor interactome: Targeting the receptor complex as a strategy for treatment of substance use disorder.

Authors:  Rong Chen; Mark J Ferris; Shiyu Wang
Journal:  Pharmacol Ther       Date:  2020-05-27       Impact factor: 12.310

2.  Prior methamphetamine self-administration attenuates the dopaminergic deficits caused by a subsequent methamphetamine exposure.

Authors:  Lisa M McFadden; Paula L Vieira-Brock; Glen R Hanson; Annette E Fleckenstein
Journal:  Neuropharmacology       Date:  2015-01-31       Impact factor: 5.250

3.  Diverse actions of the modulatory peptide neurotensin on central synaptic transmission.

Authors:  Christopher W Tschumi; Michael J Beckstead
Journal:  Eur J Neurosci       Date:  2018-02-28       Impact factor: 3.386

4.  Imidazole-derived agonists for the neurotensin 1 receptor.

Authors:  Paul M Hershberger; Michael P Hedrick; Satyamaheshwar Peddibhotla; Arianna Mangravita-Novo; Palak Gosalia; Yujie Li; Wilson Gray; Michael Vicchiarelli; Layton H Smith; Thomas D Y Chung; James B Thomas; Marc G Caron; Anthony B Pinkerton; Lawrence S Barak; Gregory P Roth
Journal:  Bioorg Med Chem Lett       Date:  2013-11-21       Impact factor: 2.823

5.  Discovery of ML314, a Brain Penetrant Non-Peptidic β-Arrestin Biased Agonist of the Neurotensin NTR1 Receptor.

Authors:  Satyamaheshwar Peddibhotla; Michael P Hedrick; Paul Hershberger; Patrick R Maloney; Yujie Li; Monika Milewski; Palak Gosalia; Wilson Gray; Alka Mehta; Eliot Sugarman; Becky Hood; Eigo Suyama; Kevin Nguyen; Susanne Heynen-Genel; Stefan Vasile; Sumeet Salaniwal; Derek Stonich; Ying Su; Arianna Mangravita-Novo; Michael Vicchiarelli; Gregory P Roth; Layton H Smith; Thomas D Y Chung; Glen R Hanson; James B Thomas; Marc G Caron; Lawrence S Barak; Anthony B Pinkerton
Journal:  ACS Med Chem Lett       Date:  2013-07-20       Impact factor: 4.345

6.  Mephedrone alters basal ganglia and limbic neurotensin systems.

Authors:  Christopher L German; Amanda H Hoonakker; Annette E Fleckenstein; Glen R Hanson
Journal:  J Neurochem       Date:  2014-04-19       Impact factor: 5.372

7.  Effect of low doses of methamphetamine on rat limbic-related neurotensin systems.

Authors:  Mario E Alburges; Amanda J Hoonakker; Nathaniel M Cordova; Christina M Robson; Lisa M McFadden; Amber L Martin; Glen R Hanson
Journal:  Synapse       Date:  2015-06-11       Impact factor: 2.562

8.  Responses of the rat basal ganglia neurotensin systems to low doses of methamphetamine.

Authors:  Mario E Alburges; Amanda J Hoonakker; Nathaniel M Cordova; Christina M Robson; Lisa M McFadden; Amber L Martin; Glen R Hanson
Journal:  Psychopharmacology (Berl)       Date:  2014-02-13       Impact factor: 4.530

9.  Response of neurotensin basal ganglia systems during extinction of methamphetamine self-administration in rat.

Authors:  Glen R Hanson; Amanda J Hoonakker; Christina M Robson; Lisa M McFadden; Paul S Frankel; Mario E Alburges
Journal:  J Pharmacol Exp Ther       Date:  2013-05-17       Impact factor: 4.030

10.  The effects of methamphetamine self-administration on cortical monoaminergic deficits induced by subsequent high-dose methamphetamine administrations.

Authors:  Lisa M McFadden; Glen R Hanson; Annette E Fleckenstein
Journal:  Synapse       Date:  2013-07-27       Impact factor: 2.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.